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The enzyme FASN (fatty acid synthase) is potentially related with hypertension and metabolic 
dysfunction. FASN is highly expressed in the human placenta. We aimed to investigate the relationship 
circulating FASN has with blood pressure, maternal metabolism and newborn parameters in healthy 
pregnant women. Circulating FASN was assessed in 115 asymptomatic pregnant women in the 
second trimester of gestation along with C-peptide, fasting glucose and insulin, post-load glucose 
lipids, HMW-adiponectin and blood pressure (the latter was assessed in each trimester of gestation). 
At birth, newborns and placentas were weighed. FASN expression was also able to be assessed in 80 
placentas. Higher circulating FASN was associated with lower systolic blood pressure (SBP), with a more 
favourable metabolic phenotype (lower fasting glucose and insulin, post load glucose, HbAc1, HOMA-IR 
and C-peptide), and with lower placental and birth weight (all p < 0.05 to p < 0.001). Placental FASN 
expression related positively to circulating FASN (p < 0.005) and negatively to placental weight 
(p < 0.05). Our observations suggest a physiological role of placental FASN in human pregnancy. Future 
studies will clarify whether circulating FASN of placental origin does actually regulate placental and 
fetal growth, and (thereby) has a favourable influence on the pregnant mother’s insulin sensitivity and 
blood pressure.
The multifunctional protein complex FASN (fatty acid synthase) is indispensable in the synthesis of saturated 
straight-chain fatty acids from acetyl coenzyme A (CoA), via malonyl-CoA1. Excess energy intake and increased 
insulin levels has the effect of upregulating the FASN gene expression2,3; suggesting this enzyme is implicated in 
energy homeostasis.
Altered FASN activity/expression has been reported in metabolic syndrome and overweight subjects who 
exhibit obesity, inflammation, hypertension, insulin resistance, dyslipidemia and atherosclerosis, indicating a 
relationship between FASN and the pathogenesis of hypertension and metabolic dysfunction4,5. Adipose tissue 
from hypertensive individuals showed decreased levels of FASN mRNA6. The subcutaneous adipose tissue of the 
obese subjects also showed decreased FASN expression compared to lean subjects7–11, and has exhibited negative 
correlation with insulin resistance markers such as glucose, HbA1c and HOMA-IR6–8. In adipose tissue of insulin 
1Pediatrics, Girona Institute for Biomedical Research, 17007 Girona, Spain. 2Pediatrics, Dr. Josep Trueta Hospital, 
17007 Girona, Spain. 3TargetsLab, Medical Sciences Department, Faculty of Medicine, University of Girona, 17003 
Girona, Spain. 4Pediatrics, Salut Empordà Foundation, 17600 Figueres, Spain. 5Obstetrics and Gynecology, Salut 
Empordà Foundation, 17600 Figueres, Spain. 6Department of Development & Regeneration, University of Leuven, 
3000 Leuven, Belgium. 7Pediatric Endocrinology Unit, Sant Joan de Déu Children’s Hospital, 08950 Esplugues, 
Barcelona. 8CIBERDEM (Center for Network Biomedical Research in Diabetes and Related Metabolic Diseases), ISCIII, 
Madrid, Spain. Correspondence and requests for materials should be addressed to A.L.-B. (email: alopezbermejo@
idibgi.org) or J.B. (email: jbassols@idibgi.org)
received: 03 August 2015
Accepted: 22 March 2016
Published: 19 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24167 | DOI: 10.1038/srep24167
resistant type 2 diabetic patients, FASN mRNA expression is markedly decreased in response to reduced insulin 
signalling12.
In vivo, the cellular concentrations of poly-unsaturated fatty acids and sterols are the main factors regulat-
ing the expression of FASN, when their concentrations decrease in the cell, the transcription of the FASN gene 
increases. FASN can be actively removed out of the cell when AMPK (adenosine monophosphate-activated pro-
tein kinase) is activated9. Circulating FASN is thus thought to reflect previous intracellular enzymatic activity9.
In normal cells, low levels of FASN are present due to abundant dietary lipids. However, FASN is highly 
expressed in hepatic, adipose tissue and in neoplastic cells, where FASN expression and the synthesis of new fatty 
acids are up-regulated as a survival advantage to low-fuel supply13,14. The placenta also expresses high amounts of 
FASN15,16. Trophoblastic cells may use de novo lipid synthesis in order to maintain essential placental actions for 
development. This strategy may also be an evolutionary favoured compensatory mechanism, as the lipid supply 
from food intake may become limited during pregnancy.
The role of FASN in human pregnancy is poorly studied. A recent report indicates that maternal obesity 
and gestational diabetes are related to less expression of FASN in adipose tissue of subcutaneous and visceral 
origin17. In mice with a lipid-poor diet during gestation, an augmented expression of FASN in adipose tissue was 
reported18.
Despite the core physiological role of FASN in maintaining normal levels of lipids and glucose, as well as 
energy homeostasis and its high expression in placenta, the relationship between the circulating form of this 
molecule, blood pressure and metabolism during human pregnancy has not been characterized. In this work, we 
studied the associations of circulating FASN with blood pressure, maternal metabolism and newborn parameters 
in normal human pregnancy. We also studied whether circulating FASN was related to placental FASN expression.
Results
Table 1 summarizes the clinical and laboratory findings of the study subjects.
Correlation analyses. Second- and third-trimester SBP decreased with increasing circulating FASN. Higher 
circulating FASN was also related to a more favourable metabolic condition, specifically lower fasting glucose and 
insulin, post load glucose, HbAc1, HOMA-IR and C-peptide (all p < 0.05 to p < 0.001; Table 2). Circulating FASN 
was inversely related to placental weight and birth weight (p < 0.05 to p < 0.01; Table 2), and directly associated 
with placental FASN mRNA expression (p < 0.001; Table 2). Placental FASN expression was also inversely related 
Clinical assessments 1st Trimester 2nd Trimester 3rd Trimester
n 115 115 115
Age (yr) 30.2 ± 0.2 – –
Height (m) 163 ± 1 – –
Weight (Kg) 66 ± 1 72 ± 1 77 ± 1
BMI (Kg/m2) 25 ± 1 27 ± 1 29 ± 1
SBP (mm Hg) 116 ± 1 117 ± 1 119 ± 1
DBP (mm Hg) 68 ± 1 69 ± 1 72 ± 1
Laboratory variables
 Pre-load glucose (mg/dL) – 78 ± 1 –
 Post-load glucose (mg/dL) – 113 ± 3 –
 HbA1C (%) – 5.0 ± 0.1 –
 Fasting insulin (μIU/mL) – 6.0 ± 0.5 –
 HOMA-IR – 1.2 ± 0.1 –
 C-peptide – 1.6 ± 0.1 –
 HMW-adiponectin (mg/L) – 6.1 ± 0.2 –
 Triacylglycerol (mg/dL) – 161 ± 1 –
 Total cholesterol (mg/dL) – 257 ± 2 –
 HDL cholesterol (mg/dL) – 71 ± 1 –
 LDL cholesterol (mg/dL) – 154 ± 2 –
 Circulating FASN (ng/mL) – 4.4 ± 0.2 –
Placental and Newborns’ Parameters
 Placental FASN expressiona – – 0.8 ± 0.1
 Placental weight (g) – – 603 ± 8
 Birth weight (g) – – 3300 ± 30
 Birth length (cm) – – 49.5 ± 0.1
 Birth weight SDS – – 0.1 ± 0.1
 Birth length SDS – – − 0.1 ± 0.1
Table 1.  Clinical and laboratory assessments in healthy pregnant women. Data are shown as mean ± SEM. 
BMI: body mass index; SBP & DBP: systolic and diastolic blood pressure; HOMA-IR: homeostasis model 
assessment insulin resistance; FASN: fatty acid synthase. aAssessed after parturition in 80 women.
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to the weight of the placenta (p < 0.05), however, it was unrelated to blood pressure or to metabolic parameters 
in pregnant women (data not shown).
Tertiles of circulating FASN. A threshold association was evident for circulating FASN and BP, metabolic 
variables and the parameters of newborns, with women in the highest tertile of circulating FASN exhibiting 
lower SBP in the second and third trimester of gestation, DBP in the third trimester, fasting glucose and insulin, 
post load glucose HOMA-IR, placental FASN expression, placental weight and birth weight SDS, and higher 
HMW-adiponectin compared to other tertiles of circulating FASN (Table 3 and Fig. 1 and Suppl Fig. 1).
Multiple regression analyses. In multiple regression analyses (Table 4), circulating FASN remained inde-
pendently related to the second- (β = − 0.231, p = 0.008) and third- (β = − 0.333, p < 0.001) trimester SBP, fasting 
and post-load glucose (β = − 0.204, p = 0.028 and β = − 0.261, p = 0.004, respectively), HOMA-IR (β = − 0.257, 
p = 0.006), and placental and birth weight (β = − 0.214, p = 0.030 and β = − 0.194, p = 0.015, respectively), even 
when confounding variables where introduced in the model.
Placental FASN expression also remained correlated to placental weight (β = − 0.238, p = 0.047) inde-
pendently of confounding variables in multivariate analyses (Table 5).
Discussion
Higher circulating FASN was associated with a more favourable blood pressure and metabolic profile, with lower 
placental weight and birth weight and with higher placental FASN expression in healthy pregnant women.
The independent associations of circulating FASN with blood pressure and with glucose- and insulin-related 
markers concur with previous reports in overweight and hypertensive subjects that showed decreased FASN 
expression in their fat depots6,19. Additionally, a negative relation between FASN expression and insulin resistance 
markers, has been reported in adipose tissue of healthy subjects without diabetes6,8. Evidence, however, exists for 
an increased FASN expression and higher circulating FASN in obesity-related disorders5,20. These discrepancies 
may be explained, at least in part, by the apparently opposing effects of insulin on FASN, causing both long-term 
upregulation of FASN expression and short-term FASN inactivation; the latter being dependent on the insuline-
mic state of the individual21. Our study was based on healthy pregnant women with no comorbidities. These 
associations may vary in patients with chronic insulin resistance including patients with vascular or metabolic 
comorbidities and long-standing obesity.
Clinical assessments 1st Trimester 2nd Trimester 3rd Trimester
Age (yr) 0.020 – –
Height (m) − 0.162 – –
Weight (Kg) − 0.149 − 0.142 − 0.137
BMI (Kg/m2) − 0.085 − 0.069 − 0.062
SBP (mm Hg) − 0.107 − 0.256** − 0.280***
DBP (mm Hg) − 0.175 − 0.116 − 0.210*
Laboratory variables
 Pre-load glucose (mg/dL) – − 0.227* –
 Post-load glucose (mg/dL) – − 0.298*** –
 HbA1C (%) – − 0.225* –
 Fasting insulin (μIU/ml) – − 0.274** –
 HOMA-IR – − 0.285** –
 C-peptide (ng/mL) – − 0.210* –
 HMW-adiponectin (mg/L) – 0.144 –
 Triacylglycerol (mg/dL) – 0.011 –
 Total cholesterol (mg/dL) – 0.016 –
 HDL cholesterol (mg/dL) – − 0.037 –
 LDL cholesterol (mg/dL) – 0.020 –
Placental and Newborns’ Parameters
 Placental FASN expressiona – – 0.348***
 Placental weight (g) – – − 0.201*
 Birth weight (g) – – − 0.194*
 Birth length (cm) – – − 0.151
 Birth weight SDS – – − 0.247**
 Birth length SDS – – − 0.174
Table 2.  Correlation analyses of circulating FASN with clinical and laboratory parameters in healthy 
pregnant women. BMI: body mass index; SBP & DBP: systolic and diastolic blood pressure; HOMA-IR: 
homeostasis model assessment insulin resistance; FASN: fatty acid synthase. aAssessed after parturition in 80 
women. *p < 0.05, **p < 0.01 and ***p < 0.005 from Pearson correlations.
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Although the metabolic regulation of FASN is not yet completely understood, these current results suggest 
that circulating FASN may be among the factors integrating blood pressure regulation and energy metabolism 
during gestation. AMPK may provide a plausible molecular mechanism for these associations. Into the cell, FASN 
activity is limited by the activation of the nuclear AMPK enzyme that removes FASN from the cytosolic milieu 
into the extracellular space9. AMPK activation is also known to protect mice from developing hypertension22 and 
metabolic disease.
Preeclampsia is a systemic disorder of pregnancy originating in the placenta. Research has demonstrated that 
several placental antiangiogenic factors are liberated into circulation during pregnancy and cause widespread 
endothelial dysfunction, hypertension and other systemic manifestations of preeclampsia23. Besides adipose tis-
sue, FASN is highly expressed in normal trophoblastic cells15. FASN provides trophoblasts with an alternative 
mechanism to maintain a regular supply of fatty acids to keep up with the metabolic demands of this organ. 
Changes in FASN activity may thus cause trophoblastic cell dysfunction which may, in turn, affect the regulation 
of blood pressure and energy metabolism during gestation. Recent data indicate that FASN expression in human 
placenta is influenced by maternal cholesterolemia and glycemia16. We do not exclude the possibility that mRNA 
FASN levels may be also associated with metabolic parameters in pregnant women with comorbidities, such as 
gestational diabetes, hypertension or dyslipidemia. Our present results suggest a better correlation of protein 
rather than mRNA levels with energy metabolism in healthy pregnant women.
Clinical assessments
Circulating FASN tertiles
0.1–1.4 ng/ml 1.4–4.3 ng/ml 4.5–18.8 ng/ml
n 38 39 38
Age (yr) 30 ± 1 29 ± 1 31 ± 1
Height (m) 163 ± 1 163 ± 1 162 ± 1
1st trimester
 BMI (Kg/m2) 26 ± 1 25 ± 1 24 ± 1
 SBP (mm Hg) 118 ± 2 119 ± 2 114 ± 2
 DBP (mm Hg) 71 ± 1 70 ± 1 67 ± 2
2nd trimester
 BMI (Kg/m2) 28 ± 1 27 ± 1 26 ± 1
 SBP (mm Hg) 119 ± 2 120 ± 1 114 ± 2*
 DBP (mm Hg) 70 ± 1 69 ± 2 68 ± 1
3rd trimester
 BMI (Kg/m2) 30 ± 1 29 ± 1 28 ± 1
 SBP (mm Hg) 123 ± 2 121 ± 2 116 ± 2**
 DBP (mm Hg) 75 ± 1 72 ± 1 70 ± 2*
Laboratory variables
 Pre-load glucose (mg/dL) 80 ± 1 80 ± 1 76 ± 1*
 Post-load glucose (mg/dL) 119 ± 5 122 ± 4 101 ± 5**
 HbA1C (%) 5.1 ± 0.1 5.0 ± 0.1 4.9 ± 0.1
 Fasting insulin (μIU/mL) 6.8 ± 0.8 5.9 ± 0.5 4.4 ± 0.7**
 HOMA-IR 1.3 ± 0.2 1.1 ± 0.1 0.8 ± 0.1**
 C-peptide 1.6 ± 0.1 1.6 ± 0.1 1.4 ± 0.1
 HMW-adiponectin (g/L) 5.8 ± 0.4 4.9 ± 0.3 6.8 ± 0.5*
 Triacylglycerol (mg/dL) 160 ± 11 175 ± 9 153 ± 8
 Total cholesterol (mg/dL) 251 ± 8 268 ± 8 254 ± 9
 HDL cholesterol (mg/dL) 68 ± 2 74 ± 2 69 ± 3
 LDL cholesterol (mg/dL) 151 ± 7 160 ± 7 153 ± 7
 Circulating FASN (ng/mL) 0.7 ± 0.1 2.8 ± 0.1 10.1 ± 1***
Placental and Newborns’ Parameters
 Placental FASN expressiona 0.6 ± 0.1 0.7 ± 0.1 1.1 ± 0.1***
 Placental weight (g) 625 ± 25 593 ± 20 585 ± 23*
 Birth weight (g) 3382 ± 53 3272 ± 50 3256 ± 47
 Birth length (cm) 50 ± 0.3 50 ± 0.2 49 ± 0.2
 Birth weight SDS 0.2 ± 0.1 0.1 ± 0.1 − 0.1 ± 0.1*
 Birth length SDS − 0.1 ± 0.2 − 0.1 ± 0.2 − 0.3 ± 0.1
Table 3.  Clinical and laboratory assessments in healthy pregnant women according to tertiles of 
circulating FASN. Data are shown as mean ± SEM. BMI: body mass index; SBP & DBP: systolic and diastolic 
blood pressure; HOMA-IR: homeostasis model assessment insulin resistance; FASN: fatty acid synthase. 
aAssessed after parturition in 80 women. *p < 0.05, **p < 0.01 and ***p < 0.001 from One-Way ANOVA.
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Our results showed negative associations of placental weight and/or birth weight with circulating FASN and 
placental FASN expression. The human placenta is comprised by a trophoblast layer that physically limits mater-
nal and fetal blood flows. Maternal plasma lipoproteins cross the placenta to supply the fetus with lipids24. Fetal 
Figure 1. Distribution of metabolic parameters: blood pressure [second- and third-trimester systolic 
blood pressure (SBP)], HMW-adiponectin, pre- and post-load glucose, insulin, HOMA-IR and placental 
FASN expression according to tertiles of circulating FASN (1st: 0.1–1.4 ng/ml; 2nd: 1.4–4.3 ng/ml and 3rd: 
4.5–18.8 ng/ml). Data are means and SEM.
(a)
SBP (mmHg)
2nd Trimester 3rd Trimester
Beta Sig. R2 Beta Sig. R2
BMI (Kg/m2) 0.373 < 0.001 15.1% 0.258 0.005 4.1%
FASN (ng/ml) − 0.231 0.008 5.3% − 0.333 < 0.001 8.1%
(b)
Metabolic Variables
Pre-load Glucose Post-load Glucose HOMA-IR
Beta Sig. R2 Beta Sig. R2 Beta Sig. R2
BMI (Kg/m2) 0.257 0.006 7.7% 0.200 0.027 3.4% 0.262 0.005 8.1%
FASN (ng/ml) − 0.204 0.028 4.7% − 0.261 0.004 7.2% − 0.257 0.006 6.6%
HOMA-IR (uIU/ml) 0.187 0.044 3.5% – – – – – –
(c)
Newborns’ Parameters
Placental Weight Birth Weight
Beta Sig. R2 Beta Sig. R2
BMI (Kg/m2) 0.247 0.020 9.2% – – –
FASN (ng/ml) − 0.214 0.030 3.9% − 0.194 0.015 3.8%
Gestational age 0.219 0.027 4.2% 0.610 < 0.001 37.4%
Table 4.  Multivariate linear models of circulating FASN and gestational SBP, metabolic variables and 
newborn’s parameters in healthy pregnant women. (a) Non-predictive variables: age, HbA1c, HOMA-IR and 
serum lipids. (b) Non-predictive variables: age and serum lipids. (c) Non-predictive variables: sex, maternal age, 
pre- or post-load glucose, HbA1c, HOMA-IR and serum lipids.
Placental Weight
Beta Sig. R2
Placental FASN expressiona − 0.238 0.047 5.6%
Gestational age 0.323 0.008 10.6%
Table 5.  Multivariate linear models of placental FASN expression and placental weight in healthy pregnant 
women. Non-predictive variables: sex, maternal age and BMI, pre- or post-load glucose, HbA1c, HOMA-IR 
and serum lipids. aAssessed after parturition in 80 women.
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tissues and the placenta also synthetize fatty acids and cholesterol to compensate for a possible lipid deficiency 
during pregnancy25.
Therefore, we would suggest that the changes in FASN expression in smaller placentas may be a compensatory 
mechanism to regulate maternal blood pressure and metabolic parameters in normal pregnancies with lower 
fetoplacental growth.
Increased FASN expression may regulate the fatty acid outflow from other tissues, such as adipose tissue, pre-
venting placentas from being too big or too small, as well as contributing to an improvement in the physiological 
insulin-resistant state that is observed during pregnancy. In this sense, during pregnancy, to compensate for a 
poor lipid diet, several adaptations of the maternal metabolism may be the increasing expression of those genes 
implicated in the synthesis of fatty acids (among them FASN) in the maternal tissues including liver, adipose 
tissue and the mammary glands18.
We are aware of some limitations in our study. A cause-effect relationship cannot be described between circu-
lating FASN and blood pressure or metabolic variables in pregnant women by the present study design. The exact 
link between circulating FASN and blood pressure in women with pathological conditions, such as preeclampsia 
or metabolic disorders cannot be discerned in our healthy study population. Moreover, circulating FASN was 
taken at a single point in the second trimester. Serial measurements of FASN throughout the pregnancy and in 
maternal hypertensive or dysglycemic conditions would have added greater value to our present results.
In conclusion, circulating FASN was associated with a more favourable blood pressure and metabolic profile 
and with lower placental and birth weight. Circulating FASN and placental FASN expression were closely related. 
Future studies will clarify whether circulating FASN of placental origin regulates placental and fetal growth, and 
(thereby) has a favourable effect on blood pressure and insulin sensitivity in the pregnant mother.
Methods
Study population and ethics. 115 pregnant Caucasian women experiencing normal pregnancies and 
delivering normal birth weight infants were included in the study. These infants were included in a prenatal 
cohort of healthy infants. The women were recruited at the Figueres Hospital26 and none of the women expe-
rienced complicated pregnancies or parturition. Women with complications, such as preeclampsia, gestational 
diabetes, fetal malformations, asphyxia and multiple pregnancies were excluded from this prenatal cohort of 
apparently healthy mothers and babies.
The Dr. Josep Trueta Hospital’s Institutional Review Board approved the protocol. All the women signed an 
informed written consent. The methods were implemented according to approved guidelines.
Assessments. All patients were subjected to clinical examinations, ultrasonograms and blood tests. Mothers 
gave information about socio-demographic characteristics, medical data during pregnancy and at delivery. 
Anthropometric measurements were derived from standard medical records27.
The weight, height, BMI (in Kg/m2) and blood pressure (both systolic and diastolic) of the pregnant women were 
assessed at each trimester of gestation. An electronic sphygmomanometer (Dinamap Pro 100, GE Healthcare, UK) 
was used on the right arm and with women in the sitting position to determine the blood pressure.
All infants were born between 37 and 42 weeks and had normal birth weights (from − 2.0 to + 2.0 DE). Within 
the first hour after delivery, infants were measured with a measuring board and weighed with a calibrated scale. 
Birth weight and length were adjusted for gestational age and sex according to regional norms28.
Analytical methods. All serum samples for assessing circulating FASN and metabolic markers were 
obtained under fasting conditions between 24 and 28 gestation weeks, when glucose tolerance assessment was 
carried out. All women were subjected to fasting glucose and oral glucose tolerance test (1 h with 50 g glucose).
The hexokinase method was used to analyse serum glucose. To determine HbA1c the ion-exchange HPLC 
method was used (Bio-Rad Laboratories, S.A. Madrid, Spain). Immuno-chemiluminiscence was used to meas-
ure serum insulin (IMMULITE 2000, Siemens Healthcare, Madrid, Spain) with a detection limit of 0.4 mIU/L 
and coefficients of variability less than 10%. HOMA-IR was calculated according to the formula: fasting insulin 
(mU/l) × fasting glucose (mM)/22.5. High-molecular-weight adiponectin was determined with enzyme-linked 
immunosorbent assay (Linco Research, Missouri, USA) with a limit of detection of 0.5 ng/mL and coefficients of 
variability less than 4%.
Serum lipids including triglycerides and HDL cholesterol were determined using routine laboratory tests. A 
quantitatie ELISA was used to measure serum FASN concentrations (FASgen Diagnostics, Baltimore, USA) with 
a limit of detection of 0.3 ng/ml and coefficients of variability less than 12%.
Placental collection. Placental tissue was studied in a representative subgroup (n = 80) of the women stud-
ied and who did not differ in clinical or laboratory parameters from the whole group. Placentas were weighed at 
the moment of delivery. Three fragments of ~1 cm3 of tissue were biopsied on the maternal side for each placenta. 
The samples were embedded in RNAlater (QIAGEN, Madrid, Spain) into cryotubes and stored at − 80 °C until 
RNA extraction.
Gene expression. Placental biopsies were each homogenized and total RNA was extracted (RNeasy Mini 
Kit; QIAGEN, Madrid, Spain) using the standard protocol with DNase. The absorbance at 260 nm was used 
for assessing RNA concentration (Spectramax Plus 384 Microplate Reader, Molecular Devices, Berkshire, UK). 
A260/A280 ratio was used to exclude protein contamination.
One microgram of RNA was converted to cDNA following the instructions of the manufacturer 
(High-Capacity RNA-to-cDNA Kit, Life Technologies SA, Madrid, Spain). To perform real time PCR 25 μl mix-
tures were prepared containing 2xTaqman Universal Master Mix (12.5 μl) (Applied Biosystems), cDNA (4 ng/μl), 
and the following Taqman Gene Expression Assays (1.25 μl) (Life Technologies SA, Madrid, Spain): FASN 
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(Hs00188012), TBP (Hs99999910) and SDHA (Hs00360422). The cycling protocol was 50 °C, 2 min; 95 °C, 
10 min; then 40 cycles of 95 °C, 15 s and 60 °C, 1 min (ABI PRISM® 7000 Sequence Detection System; Life 
Technologies SA, Madrid, Spain). The 2− ΔΔCT method was used to calculate the relative expression using the Ct 
values of the housekeeping genes TBP and SDHA27.
Statistics. Results are expressed as mean ± SEM. Statistical analyses were performed using SPSS statistics 
software (IBM, Madrid, Spain). Logarithmic transformation was used to restore symmetry of non-parametric 
variables. Pearson correlation test and multiple regression analyses in a stepwise manner were used to analyze 
the association between quantitative variables. Variables of interest were also analysed by One-Way ANOVA 
according to tertiles of circulating FASN and p < 0.05 was used as the significance level. The study exhibited a 
power of 80% and a 0.26 Pearson’s correlation coefficient to detect a significant association between serum FASN, 
blood pressure and metabolic parameters, and a 0.30 Pearson’s correlation coefficient between serum FASN and 
placental FASN expression.
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